By continuing to use the site you agree to our Privacy & Cookies policy

Room temperature version of coagulation factor

Novo Nordisk UK has announced that NovoSeven – its recombinant activated factor VII product available for the treatment of bleeding episodes in people with haemophilia with inhibitors – is now available as a room temperature stable formulation from today onwards. This replaces the previous formulation, which required refrigeration.

This new formulation, which is stable at temperatures up to 25°C, enables patients to administer treatment effectively and quickly after the onset of bleeding in any setting.

Have your say

You must sign in to make a comment.

Related Jobs

Sign in to see the latest jobs relevant to you!